ENGENE THERAPEUTICS INC
ENGNNASDAQTrading Snapshot
- Day Range
- $1.80 – $1.86
- 52-Week Range
- $1.40 – $12.25
- Volume
- $2.24B
- Avg Volume
- $1.57B
- Shares Outstanding
- 67.0M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $3M
- P/E Ratio
- -1.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.95
- Dividend Yield
- 0.00%
Why Investors Own ENGN
- ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ENGENE THERAPEUTICS INC
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer August 11, 2026 11:00 AM EDTCompany...
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - Slideshow
2026-08-11. The following slide deck was published by enGene Therapeutics Inc.
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL, August 04, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dri
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL, July 16, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid ("detalimogene") if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk non-m
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing